Today: 21 May 2026
Glencore stock jumps on Rio Tinto takeover talks — the deadline and next catalysts investors watch
9 January 2026
2 mins read

Glencore stock jumps on Rio Tinto takeover talks — the deadline and next catalysts investors watch

London, Jan 9, 2026, 10:45 GMT — Regular session

  • Glencore shares rose about 8% after the company confirmed preliminary discussions with Rio Tinto on a possible combination
  • The talks are at an early stage and could involve an all-share deal, with UK takeover rules setting a Feb. 5 decision deadline
  • Investors are watching for further deal detail and for Glencore’s next scheduled updates later this month and in February

Glencore plc shares jumped on Friday after the miner and commodities trader confirmed it is in preliminary talks with Rio Tinto about a possible tie-up that could include an all-share merger. Glencore’s share price tools showed the stock at 447.83 pence, up 34.83 pence, by 10:00 GMT, with prices delayed by 10 minutes. 

The revived talks land as big miners jostle for metals such as copper, used in power grids and data centres, and after a run of dealmaking across the sector. A combination of Rio and Glencore would create the world’s largest miner by market value at roughly $207 billion, according to Reuters calculations, overtaking BHP. 

The market reaction was lopsided: Glencore surged while Rio’s shares fell, a split that typically signals the target is seen as the main winner. “Investors are not happy with this,” said Hugh Dive, chief investment officer at Atlas Funds Management, which holds Rio stock. Others warned Rio would need a clean plan for Glencore’s coal exposure to bring shareholders along. Reuters

Both companies said the discussions are preliminary and there is no certainty an offer will be made or on what terms. Rio said the current expectation is an all-share merger — paid in stock rather than cash — structured through a UK “scheme of arrangement”, a court-approved process often used in takeovers. Under UK takeover rules, Rio has until 5 p.m. London time on Feb. 5 to announce a firm intention to make an offer or to walk away, unless the Takeover Panel grants an extension. Investegate

Supporters argue the strategic logic is straightforward: Rio needs more copper and Glencore brings it, along with a big marketing arm that throws off cash in volatile markets. “It was better to buy producing assets rather than to wait to build new mines,” Berenberg analyst Richard Hatch said, adding Rio needs more copper as “the market (rightly or wrongly) views iron ore as a commodity facing price decline.” The two groups have discussed combining before, including talks that ended without a deal in late 2024. Reuters

But big mining tie-ups have a habit of stalling once the hard work starts, and the list of potential obstacles is long — from antitrust reviews to the question of what sits where in a combined portfolio. Morningstar’s Michael Field said scepticism was warranted: “We’ve seen this before where deal talks in this industry roll on for a few months and then fall apart.” Glencore’s move on Friday pushed the stock to its highest level since July 2024, adding to the pressure for both sides to explain the numbers quickly. Reuters

Outside markets, the politics are awkward. In a sector pushing to polish its energy-transition credentials, Glencore is still a major coal producer, and investors have flagged coal as a sticking point in earlier talks, along with valuation and leadership questions. “Last year’s theme of consolidation in the natural resources sector has shown no sign of let-up in the early part of 2026,” said Derren Nathan, head of equity research at Hargreaves Lansdown. The Guardian

For Glencore stock, the near-term calendar now matters as much as the rumour mill. The company’s corporate calendar lists a full-year production and resources and reserves update for Jan. 29 and preliminary annual results for Feb. 18, the next fixed dates for new numbers as deal speculation swirls. 

Stock Market Today

  • SpaceX IPO Filing Reveals Financials, Musk Could Become First Trillionaire
    May 20, 2026, 7:08 PM EDT. SpaceX filed for an initial public offering (IPO), disclosing its finances and board members for the first time. The company reported $18.7 billion in revenue for 2025, up 33% year-on-year, but posted a net loss of $4.9 billion, reversing a $791 million profit in 2024. First-quarter 2026 losses reached $4.3 billion on $4.7 billion revenue. The IPO, trading as SPCX, may become the largest ever, potentially boosting Elon Musk's wealth to trillionaire status. SpaceX aims to fund its ambitious plans including Starlink satellite network expansion, AI infrastructure, and establishing extraterrestrial colonies.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
AbbVie stock slides on $1.3 billion charge and outlook cut as deal chatter swirls
Previous Story

AbbVie stock slides on $1.3 billion charge and outlook cut as deal chatter swirls

Ondas stock jumps again in premarket after SEC resale filing, with insider sale notice in the mix
Next Story

Ondas stock jumps again in premarket after SEC resale filing, with insider sale notice in the mix

Go toTop